The immune response to severe bacterial infections: Consequences for therapy

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 369-380

  Giamarellos Bourboulis, Evangelos J ^a   Raftogiannis, Maria ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

apoptosis; bacterial infections; cytokines; immunostimulation; macrolides; monocytes; sepsis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERITORAN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PATTERN RECOGNITION RECEPTOR; PLACEBO; POLYMYXIN B; SIMVASTATIN; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; APOPTOSIS; BACTERIAL INFECTION; CLINICAL PRACTICE; CLONAL ANERGY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; HEMOPERFUSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LOADING DRUG DOSE; MONOCYTE; NONHUMAN; REVIEW; SEPSIS; T LYMPHOCYTE ACTIVATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; BACTERIAL INFECTIONS; HEMOPERFUSION; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84858173181     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.2     Document Type: Review

References (93)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29(7), 1303-1310 (2001). (Pubitemid 32641789)
2. Bosmann M, Russkamp NF, Patel VR, Zetoune FS, Sarma JV, Ward PA. The outcome of polymicrobial sepsis is independent of T and B cells. Shock 36(4), 396-401 (2011).
3. Beutler BA. TLRs and innate immunity. Blood 113(7), 1399-1407 (2009).
4. Weighardt H, Holzmann B. Role of Toll-like receptor response for sepsis pathogenesis. Immunobiology 212(9-10), 715-722 (2008). (Pubitemid 350246264)
5. Jin X, Lin Z, Xie X. The delayed response of Toll-like receptors may relate to Pseudomonas aeruginosa keratitis exacerbating rapidly at the early stages of infection. Eur. J. Clin. Microbiol. Infect. Dis. 29(2), 231-238 (2010).
6. Spiller S, Elson G, Ferstl R et al. TLR-induced IFN-gproduction increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J. Exp. Med. 205(8), 1747-1754 (2008).
7. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10(7), 479-490.
8. Smith RP, Baltch AL, Ritz WJ, Michelsen PB, Bopp LH. IFN-genhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively that GM-CSF in the presence of daptomycin and other antibiotics. Cytokine 51(3), 274-277 (2010).
9. Lordoo D, Marques A, Hornung RL, Cadavid D. IL-10 helps control pathogen load during high-level bacteremia. J. Immunol. 181(3), 2076-2083 (2008).
10. van der Poll T, van Zoelen MAD, Wiersinga WJ. Regulation of pro-and anti-inflammatory host responses. Contrib. Microbiol. 17, 125-136 (2011).
11. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
12. Porfyridis I, Plachouras D, Karagianni V et al. Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect. Dis. 10, 286 (2010).
13. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 21(1), 38-46 (2009).
14. Gibot S, Kolopp-Sarda MN, Béné MC et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med. 200(11), 1419-1426 (2004). (Pubitemid 39657289)
15. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat. Immunol. 10(10), 1065-1073 (2009).
16. Sharma S, De Oliveira RB, Kalantari P et al. Innate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genome. Immunity 35(2), 194-207 (2011).
17. Kinjo Y, Illarionov P, Vela JL et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat. Immunol. 12(10), 966-975 (2011).
18. Giamarellos-Bourboulis EJ. What is the pathophysiology of the septic host upon admission? Int. J. Antimicrob. Agents 36(Suppl. 2), S2-S5 (2010).
19. Uhlig HH, McKenzie BS, Hue S et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25(2), 309-318 (2006).
20. O'Dwyer MJ, Mankan AK, White M et al. The human response to infection is associated with distinct patterns of interleukin 23 and interleukin 27 expression. Intensive Care Med. 34(4), 683-691 (2008).
21. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur. J. Immunol. 40(7), 1830-1835 (2010).
22. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34, 1084-1093 (2003).
23. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am. J. Emerg. Med. 26(6), 711-715 (2008). (Pubitemid 351905818)
24. Bozza FA, Salluh JI, Japiassu AM et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care 11(2), R49 (2007).
25. Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 29(3), 328-333 (2008). (Pubitemid 351271703)
26. Emonts M, Sweep FC, Grebenchtchikov N et al. Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Crit. Care Med. 44(10), 1321-1328 (2007). (Pubitemid 46717294)
27. Lukaszewicz AC, Grienay M, Resche-Rigon M et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit. Care Med. 37(10), 2746-2752 (2009).
28. Sinistro A, Almerighi C, Ciaprini C et al. Downregulation of CD40 ligand response in monocytes form sepsis patients. Clin. Vacc. Immunol. 15(12), 1851-1858 (2008).
29. Giamarellos-Bourboulis EJ, van de Veerdonk FL, Mouktaroudi M et al. Inhibition of caspase-1 activation in Gram-negative sepsis and experimental endotoxemia. Crit. Care 15(1), R27 (2011).
30. O'Dwyer MJ, Mankan AK, Stordeur P et al. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 26(6), 544-550 (2006). (Pubitemid 44789626)
31. Dimopoulou I, Pelekanou A, Mavrou I et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: Correlation with monocyte gene expression. J. Crit. Care doi:10.1016/j. jcrc.2011.06.013 (2011) (Epub ahead of print).
32. Muenzer JT, Davis CG, Chang K et al. Characterization and modulation of the immunosuppressive phase of sepsis. Infect. Immun. 78(4), 1582-1592 (2010).
33. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 181(1), 176-180 (2000). (Pubitemid 30049046)
34. Giamarellos-Bourboulis EJ, Zakynthinos S, Baziaka F et al. Soluble triggering receptor expressed on myeloid cells 1 as an anti-inflammatory mediator in sepsis. Intensive Care Med. 32(2), 237-243 (2006). (Pubitemid 43251144)
35. Kessel A, Bamberger E, Masalha M, Toubi E. The role of T regulatory cells in sepsis. J. Autoimmun. 32(3-4), 211-215 (2009).
36. Venet F, Pachot A, Debard AL et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177(9), 6540-6547 (2006). (Pubitemid 44628873)
37. Venet F, Chung CS, Kherouf H et al. Increased circulating regulatory T cells (CD4+CD25+CD127-) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 35(4), 678-686 (2009).
38. Hotchkiss RS, Tinsley K W, Swanson PE et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166(11), 6952-6953 (2001).
39. Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leucocyte apoptosis and its significance in sepsis and shock. J. Leukoc. Biol. 78(2), 325-337 (2005). (Pubitemid 41061305)
40. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J. Leukoc. Biol. 86(2), 219-227 (2009).
41. Martignoni A, Tschöp J, Goetzman HS et al. CD4-expressing cells are early mediators of the innate immune system during sepsis. Shock 29(5), 591-597 (2008). (Pubitemid 351544079)
42. Chang KC, Unsinger J, Davis CG et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J. 21(3), 708-719 (2007). (Pubitemid 46348247)
43. Schmidt MV, Paulus P, Kuhn AM et al. Peroxisome proliferator-activated receptor g-induced T cell apoptosis reduces survival during polymicrobial sepsis. Am. J. Resp. Crit. Care Med. 184(1), 64-74 (2011).
44. Vaki I, Kranidioti H, Karagianni V et al. An early circulating factor in severe sepsis modulates apoptosis of monocytes and lymphocytes. J. Leukoc Biol. 89(3), 343-349 (2011).
45. Rosas-Ballina M, Ochani M, Parrish WR et al. Splenic nerve is required for cholinergic anti-inflammatory pathway control of TNF in endotoxemia. Proc. Natl Acad. Sci. USA 105(31), 11008-11013 (2008).
46. Su X, Matthay MA, Malik AB. Requisite role of the cholinergic a7 nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced acute lung inflammatory injury. J. Immunol. 184(1), 401-410 (2009).
47. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J. Immunol. 180(9), 6334-6345 (2008).
48. Hu CK, Venet F, Heffernan DS, Wang YL et al. The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock. J. Immunol. 182(4), 2467-2475 (2009).
49. Kim JH, Kim SJ, Lee IM et al. Bacterial endotoxin induces the release of high mobility group box a via the IFN-b signaling pathway. J. Immunol. 182(4), 2458-2466 (2009).
50. Gibot S, Massin F, Cravoisy A et al. High mobility group box 1 protein plasma concentrations during septic shock. Intensive Care Med. 33(8), 1347-1353 (2007). (Pubitemid 47101699)
51. Silva E, Arcaroli J, He Q et al. HMGB1 and LPS induce distinct patterns of gene expression and activation in neutrophils from patients with sepsis-induced acute lung injury. Intensive Care Med. 33(10), 1829-1839 (2007). (Pubitemid 47476646)
52. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat. Immunol. 8(10), 776-786 (2008).
53. Zhang Q, Raoof M, Chen Y et al. Circulating mitochondrial DAMPs cause inflammation response to injury. Nature 464(7285), 104-108 (2010).
54. Pelekanou A, Tsangaris I, Kotsaki A et al. Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit. Care 13(6), R172 (2009).
55. Gogos C, Kotsaki A, Pelekanou A et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit. Care 14(3), R96 (2010).
56. van Zoelen MAD, Laterre PF, van Veen SQ et al. Systemic and local high mobility group box 1 concentrations during severe infections. Crit. Care Med. 35(12), 2799-2804 (2007). (Pubitemid 350175778)
57. Kasten KR, Prakash PS, Unsinger J et al. Interleukin-7 (IL-7) treatment accelerates neutrophils recruitment through gd T-cell IL-17 production in a murine model of sepsis. Infect. Immun. 78(11), 4714-4722 (2010).
58. Flohé SB, Agrawal H, Flohé S, Rani M, Bangen JM, Schade FU. Diversity of interferon gand granulocyte-macrophage-colony stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol. Med. 14(5-6), 247-256 (2008). (Pubitemid 351785697)
59. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15(1), R58 (2011).
60. Stephens DP, Thomas JH, Dip G et al. Randomized, double-blind, placebo-controlled trials of ganulocyte colony stimulating factor in patients with septic shock. Crit. Care Med. 36(2), 448-454 (2008). (Pubitemid 351158618)
61. Cheng AC, Limmathurotsakul D, Chierakul W et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin. Infect. Dis. 45(3), 308-314 (2007). (Pubitemid 47101026)
62. Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Rinsky MR. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in non-neutropenic patients. Chest 127(6), 2139-2150 (2005).
63. Schefold JC, Zeden JP, Pschowski R et al. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand. J. Infect. Dis. 42(3), 164-171 (2010).
64. Hall MW, Knatz NL, Vetterly C et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37(3), 525-532 (2011).
65. Döcke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-gtreatment. Nat. Med. 3(6), 678-681 (1997). (Pubitemid 27264980)
66. Cruz DN, Perazella MA, Bellomo R et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit. Care 11(2), R47 (2007).
67. Shimizu T, Hanasawa K, Sato K et al. Direct hemoperfusion with polymyxin-B-immobilized fiber columns improves septic hypotension and reduces inflammatory mediators in septic patients with colorectal perforation. Langenbecks Arch. Surg. 394(2), 303-311 (2009).
68. Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit. Care 9(6), R653-R661 (2005).
69. Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am. J. Surg. 188(2), 150-156 (2004). (Pubitemid 38916733)
70. Vincent JL, Laterre PF, Cohen J et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23(5), 400-405 (2005). (Pubitemid 40571661)
71. Cruz DN, Antonelli M, Fumagalli R et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23), 2445-2452 (2009).
72. Mitaka C, Tsuchida N, Kawada K, Nakajima Y, Imai T, Sasaki S. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock 32(5), 478-483 (2009).
73. Mullarkey M, Rose JR, Bristol J et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304(3), 1093-1102 (2003). (Pubitemid 36254422)
74. Tidswell M, Tillis W, LaRosa SP et al. Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med. 38(1), 72-83 (2010).
75. Kalil AC, Larosa SP, Gogate J, Lynn M, Opal SM. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 36(4), 327-331 (2011).
76. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int. J. Antimicrob. Agents 31(1), 12-20 (2008). (Pubitemid 350236720)
77. García Vázquez E, Mensa J, Martínez JA et al. Lower mortality among patients with community-acquired pneumonia treated with a aacrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur. J. Clin. Microbiol. Infect. Dis. 24, 190-195 (2005). (Pubitemid 40576665)
78. Martínez, JA, Horcajada JP, Almela M et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 36, 389-395 (2003). (Pubitemid 36241302)
79. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur. Respir. J. 33(1), 153-159 (2009).
80. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin. Infect. Dis. 46(8), 1157-1164 (2008). (Pubitemid 351589897)
81. Chastre J, Wolff W, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 290(19), 2588-2598 (2003). (Pubitemid 37443289)
82. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Srensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch. Intern. Med. 168(19), 2081-2087 (2008).
83. O' Neal HR Jr, Koyama T, Koehler EAS et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acure respiratory distress syndrome. Crti. Care Med. 39(6), 1343-1350 (2011).
84. Novack V, Eisinger M, Frenkel A et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med. 35(7), 1255-1260 (2009).
85. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr. Drug Targets 8(4), 493-500 (2007). (Pubitemid 46672616)
86. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta 1799(1-2), 149-156 (2010).
87. Dellinger RP, Levy MM, Carlet JM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36(1), 296-327 (2008).
88. Hellenic Sepsis Study Group. www.sepsis.gr
89. Lilly announces withdrawal of Xigris following recent clinical trial results. https://investor.lilly.com/releasedetail2. cfm?ReleaseID=617602
90. A study to compare the efficacy and safety of 2 dosing regimens of IV infusions of AZD9773 (CytoFab™) with placebo in adult patients with severe sepsis and/or septic shock. http://clinicaltrials.gov/ct2/show/ NCT01145560
91. ACCESS: A controlled comparison of eritoran tetrasodium and placebo in patients with severe sepsis. http://clinicaltrials.gov/ct2/show/record/ NCT00334828
92. Eisai's sepsis drug eritoran fails to save more lives in final-stage study. www.bloomberg.com/news/2011-01-25/ eisai-s-sepsis-drug-eritoran-fails-to- save-more-lives-in-final-stage-study.html
93. Clarithromycin as immunomodulator for the management of sepsis. http://clinicaltrials.gov/ct2/show/ NCT01223690